vimarsana.com
Home
Live Updates
National Medical Products Administration (NMPA) Approves Chipscreen Biosciences Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma : comparemela.com
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma
/PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative...
Related Keywords
Feng Wang ,
Hunan ,
China ,
Shanghai ,
Shenzhen ,
Guangdong ,
Chengdu ,
Sichuan ,
United States ,
Japan ,
Beijing ,
Taiwan ,
American ,
Chinese ,
Ruihua Xu ,
Sun Yat ,
Xianping Lu ,
Chidamide Tucidinostat ,
Chipscreen Biosciences ,
Weili Zhao ,
Chidamide Epidaza ,
Data Monitoring Committee ,
Chipscreen Biosciences United States Co Ltd ,
Prnewswire Shenzhen Chipscreen Biosciences Co Ltd ,
Chengdu Small Molecule Early Rd Center ,
Shanghai Jiao Tong University School Of Medicine ,
Chengdu Regional Head Office Rd Center ,
Shenzhen Chipscreen Biosciences Co Ltd ,
Shenzhen Small Molecule Early Rd Center ,
Innovative Drug Development ,
Shenzhen Head Office Rd Center ,
National Science ,
Treatment Center ,
National Medical Products Administration ,
American Society Of Clinical Oncology ,
Shanghai Branch ,
Stock Symbol ,
Independent Data Monitoring Committee ,
American Society ,
Clinical Oncology ,
Annual Meeting ,
General Manager ,
Professor Feng Wang ,
Cancer Prevention ,
Nature Medicine ,
Professor Weili Zhao ,
Ruijin Hospital ,
Shanghai Jiao Tong University School ,
Mainland China ,
Shenzhen Head ,
Chengdu Regional Head ,
Beijing Branch ,
Innovative Drug ,
Shenzhen Chipscreen Biosciences Co ,
Td ,
comparemela.com © 2020. All Rights Reserved.